Medicine shifts overnight.
15% of CRCs are dMMR.
Surgery was standard—until now.
Diaz, Cercek @mskcancercenter.bsky.social @nejm.org: dostarlimab = 82% CR, 92% RFS, low toxicity.
Immunotherapy first. Surgery backup.
Paper: nejm.org/doi/full/10.1056/NEJMoa2404512
#Lynch #CRC #Immunotherapy
nejm.org
Nonoperative Management of Mismatch Repair–Deficient Tumors | NEJM
Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer,
neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion
of patients. Whether this ...
